More than a decade of work bonds Pfizer Inc. with Wachtell, Lipton, Rosen & Katz, and Mylan NV has ties with Cravath, Swaine & Moore that are just as deep.

So it’s no surprise that the drug makers tapped top partners from those Wall Street mainstays for their $48 billion deal to create a new generic drug giant.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]